Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of the drug is set to continue. Announced in the company’s Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback